Agilent anticipates genomics market growth with expansion in Texas

By Brittany Farb Gruber

- Last updated on GMT

(Image: Getty/SergeyNivens)
(Image: Getty/SergeyNivens)
Agilent's 15,000-square-foot expansion will increase its capacity to meet a growing demand for next-generation sequencing products from its genomics group.

The expanded facility will include cold chain storage required for temperature-sensitive genomic and bioreagent products.

“Following in the wake of recent natural disasters and severe weather events, we are taking steps to further ensure continuous service to customers,”​ said Henrik Ancher-Jensen, senior vice president, Agilent, and president of order fulfillment and supply chain, in a statement.

The expansion comes on the heels of Agilent completing its acquisition of Lasergen, a biotechnology company that researches and develops technologies for DNA sequencing. Agilent made an initial investment in the Houston, TX-based company in 2016 and since then, the companies have collaborated to develop a workflow solution for clinical applications based on next-generation sequencing.

“In 2016 we began our collaboration with Lasergen that reinforced our confidence in the team and technology,”​ said Kamni Vijay, vice president and general manager of Agilent’s genomics division, in a press release announcing the completed acquisition.

“As a unified team, we now have new opportunities to leverage our combined strengths and create significant value for our customers as we work towards our goal of creating an integrated clinical workflow solution and providing more labs with access to molecular diagnostics,”​ Vijay added.

Related news

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us

Products

View more

Webinars